Bisrat Debeb
@debeblab.bsky.social
Associate Professor at MD Anderson Cancer Center- investigating the biology of brain metastasis in aggressive breast cancers, Inflammatory breast cancer (IBC), TNBC. Posts are my own.
Reposted by Bisrat Debeb
UPDATE: The pause was scrapped Tuesday evening after intervention by top White House officials. www.wsj.com/politics/pol...
Trump Administration Scraps Effort to Pause Health-Research Funding
The administration halted and then restarted billions in new research grants flowing from the National Institutes of Health.
www.wsj.com
July 30, 2025 at 3:38 AM
UPDATE: The pause was scrapped Tuesday evening after intervention by top White House officials. www.wsj.com/politics/pol...
Importantly, we show that sEcad remodels the brain microenvironment by promoting reactive astrocytes through the CXCL1–CXCR2 axis; blocking this pathway reduced brain metastasis burden and prolonged mouse survival.
June 27, 2025 at 12:33 AM
Importantly, we show that sEcad remodels the brain microenvironment by promoting reactive astrocytes through the CXCL1–CXCR2 axis; blocking this pathway reduced brain metastasis burden and prolonged mouse survival.
Using novel IBC brain metastasis models, we show that sEcad drives brain metastasis by impacting multiple steps of the metastatic cascade, including invasion, anoikis resistance, endothelial adhesion, and BBB transmigration.
June 27, 2025 at 12:32 AM
Using novel IBC brain metastasis models, we show that sEcad drives brain metastasis by impacting multiple steps of the metastatic cascade, including invasion, anoikis resistance, endothelial adhesion, and BBB transmigration.
We describe novel tumor cell-intrinsic and - extrinsic mechanisms by which soluble E-cadherin (sEcad) promotes brain metastatic growth in aggressive breast cancers. Serum sEcad levels are correlated with increased development of brain metastasis and death in breast cancer patients.
June 27, 2025 at 12:31 AM
We describe novel tumor cell-intrinsic and - extrinsic mechanisms by which soluble E-cadherin (sEcad) promotes brain metastatic growth in aggressive breast cancers. Serum sEcad levels are correlated with increased development of brain metastasis and death in breast cancer patients.